| Literature DB >> 34900686 |
Xiaolei Gao1,2,3,4, Na Zhao5,6,7, Liying Dong2, Xuan Zheng2, Yixin Zhang2, Chong Ding1,2, Shuyan Zhao8, Zeyun Ma9, Yixiang Wang1,2.
Abstract
SIMPLEEntities:
Keywords: TP53 status; head and neck squamous cell carcinoma; immune characteristics; lipid-related prognostic signature; survival
Year: 2021 PMID: 34900686 PMCID: PMC8655234 DOI: 10.3389/fonc.2021.735993
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
The lipid-related DEGs among GSE30784, GSE37991, and TCGA.
| Genes | LogFC |
| Functions |
|---|---|---|---|
| APOC2 | 2.17 | 5.02E−08 | Cholesterol metabolism |
| ADCY3 | 0.71 | 1.08E−10 | Regulation of lipolysis in adipocytes |
| ACOT7 | 1.23 | 3.22E−19 | Fatty acid elongation |
| CYP27B1 | 2.48 | 4.06E−20 | Steroid biosynthesis |
| CERS2 | 0.62 | 1.42E−10 | Sphingolipid metabolism |
| DHCR7 | 1.01 | 3.61E−06 | Steroid biosynthesis |
| GLA | 0.76 | 1.09E−12 | Sphingolipid metabolism; glycerolipid metabolism |
| GPX7 | 1.00 | 8.32E−07 | Arachidonic acid metabolism |
| GPX8 | 1.28 | 1.69E−14 | Arachidonic acid metabolism |
| GNAI1 | 0.76 | 7.48E−09 | Regulation of lipolysis in adipocytes |
| HSD17B6 | 2.11 | 3.21E−37 | Steroid hormone biosynthesis |
| HACD3 | 0.66 | 4.74E−13 | Fatty acid elongation; fatty acid metabolism; biosynthesis of unsaturated fatty acids |
| LPCAT1 | 1.72 | 8.18E−27 | Glycerophospholipid metabolism; ether lipid metabolism |
| MMP1 | 3.08 | 1.22E−13 | PPAR signaling pathway |
| OLR1 | 2.04 | 7.42E−10 | PPAR signaling pathway |
| PCSK9 | 2.77 | 1.62E−19 | Cholesterol metabolism |
| PLPP4 | 4.34 | 3.17E−27 | Glycerophospholipid metabolism; glycerolipid metabolism |
| PIK3CD | 1.24 | 3.39E−16 | Regulation of lipolysis in adipocytes |
| PPT1 | 0.77 | 1.85E−15 | Fatty acid elongation; fatty acid metabolism |
| PLA2G7 | 1.98 | 2.09E−17 | Ether lipid metabolism |
| SCARB1 | 0.73 | 3.19E−06 | Fat digestion and absorption; cholesterol metabolism |
| SLC16A1 | 1.37 | 2.64E−17 | Fatty acid biosynthesis |
| SQLE | 0.82 | 4.82E−08 | Steroid biosynthesis |
| SCD5 | 0.93 | 6.99E−08 | Fatty acid metabolism; biosynthesis of unsaturated fatty acids; PPAR signaling pathway; AMPK signaling pathway |
| SPHK1 | 1.08 | 1.68E−11 | Sphingosine degradation; sphingolipid metabolism |
| SLC2A1 | 1.76 | 1.40E−18 | Adipocytokine signaling pathway |
| ADH1B | −5.36 | 9.21E−79 | Fatty acid degradation |
| ADCY2 | −2.20 | 1.24E−16 | Regulation of lipolysis in adipocytes |
| AQP7 | −4.11 | 2.31E−94 | Regulation of lipolysis in adipocytes |
| ALOX12 | −2.51 | 1.43E−29 | Arachidonic acid metabolism |
| ACER1 | −2.50 | 8.28E−17 | Sphingosine biosynthesis; sphingolipid metabolism |
| ADIPOQ | −5.67 | 7.00E−43 | Adipocytokine signaling pathway; PPAR signaling pathway; AMPK signaling pathway |
| ASPG | −1.47 | 2.44E−10 | Cholesterol metabolism |
| ACADSB | −1.68 | 1.66E−43 | Fatty acid degradation; fatty acid metabolism |
| ADH7 | −1.79 | 8.69E−09 | Fatty acid degradation |
| CYP3A5 | −3.05 | 3.18E−54 | Steroid hormone biosynthesis |
| CYP11A1 | −2.21 | 4.01E−15 | Steroid hormone biosynthesis |
| CAB39L | −2.14 | 6.29E−111 | AMPK signaling pathway |
| CHPT1 | −1.64 | 5.19E−23 | Ether lipid metabolism; glycerophospholipid metabolism; phosphatidylcholine (PC) biosynthesis |
| CH25H | −1.60 | 1.70E−16 | Primary bile acid biosynthesis |
| CYP2E1 | −1.89 | 9.28E−14 | Steroid hormone biosynthesis; arachidonic acid metabolism; linoleic acid metabolism |
| CYP2J2 | −1.63 | 1.15E−25 | Arachidonic acid metabolism; linoleic acid metabolism |
| DEGS2 | −1.69 | 5.96E−14 | Ceramide biosynthesis; sphingosine biosynthesis; sphingolipid metabolism |
| EPHX2 | −1.63 | 3.40E−26 | Arachidonic acid metabolism |
| FABP3 | −3.03 | 3.73E−49 | PPAR signaling pathway |
| GDPD3 | −2.25 | 4.37E−30 | Ether lipid metabolism |
| GPX3 | −2.45 | 2.91E−44 | Arachidonic acid metabolism |
| GPD1L | −2.66 | 2.88E−117 | Glycerophospholipid metabolism |
| GPD1 | −5.09 | 6.26E−148 | Glycerophospholipid metabolism |
| HMGCS2 | −4.71 | 5.67E−51 | Synthesis and degradation of ketone bodies; PPAR signaling pathway; MVA pathway |
| LIPE | −1.35 | 7.95E−18 | Regulation of lipolysis in adipocytes |
| MGLL | −1.95 | 1.49E−44 | Regulation of lipolysis in adipocytes; glycerolipid metabolism; acylglycerol degradation |
| PLA2G2A | −2.52 | 8.11E−15 | Fat digestion and absorption; ether lipid metabolism; glycerophospholipid metabolism; arachidonic acid metabolism; linoleic acid metabolism; alpha-linolenic acid metabolism |
| PLIN1 | −5.44 | 4.74E−149 | Regulation of lipolysis in adipocytes; PPAR signaling pathway |
| PLIN4 | −4.40 | 6.43E−114 | PPAR signaling pathway |
| PLIN5 | −3.28 | 5.54E−69 | PPAR signaling pathway |
| PLA2G16 | −1.48 | 2.10E−13 | Regulation of lipolysis in adipocytes; ether lipid metabolism; glycerophospholipid metabolism; arachidonic acid metabolism; linoleic acid metabolism; alpha-linolenic acid metabolism |
| PTGDS | −1.76 | 2.86E−16 | Arachidonic acid metabolism |
| PPARG | −2.21 | 5.74E−29 | PPAR signaling pathway |
| SLC2A4 | −4.30 | 6.92E−102 | Adipocytokine signaling pathway |
| SLC27A6 | −3.55 | 1.00E−38 | PPAR signaling pathway |
| SORBS1 | −2.76 | 3.87E−64 | PPAR signaling pathway |
| SULT2B1 | −1.50 | 1.13E−11 | Steroid hormone biosynthesis |
| SORT1 | −1.43 | 3.82E−31 | Cholesterol metabolism |
| TM7SF2 | −1.82 | 5.62E−26 | Cholesterol biosynthesis; steroid biosynthesis |
LogFC, log Fold Change.
Figure 1Lipid-related differentially expressed genes (DEGs) in HNSCC. Top 20 of the 65 genes involving lipid metabolism showed abnormal expression in HNSCC from the TCGA database including 44 normal tissues and 502 tumors (p < 0.01, |logFC| > 2). The color from blue to red represents the gene expressions from high to low between tumors vs. normal tissues.
Figure 2Functional vanalyses and PPT network of the DEGs. (A) GO analysis including biological processes, cellular components, and molecular functions. The x-axis shows gene counts enriched in these processes. (p < 0.01, FDR < 0.05). (B) Pathway analysis of the DEGs showed the common pathways in the KEGG database. The size of the points represented the numbers of the enriched genes; the bigger the size, the more genes enriched. Blue to red points represented statistical significance from low significance to high significance (p < 0.01, FDR < 0.05). (C) PPI network of the DEGs. Blue represents down-expressed genes, and red denotes up-expressed genes. Solid lines represent known interactions from curated databases or experimentally determined. Dotted lines represent predicted interactions. (D, E) Key module genes, namely, module 1 and module 2, with scores of 6.17 and 4.5, respectively.
Figure 3Prognostic analysis of LRPS genes. (A) Univariate Cox analysis of OLR1, ADCY2, and LIPE. (B) Survival analysis of the three genes in HNSCC according to the Kaplan–Meier Plotter online database (http://kmplot.com/analysis/index.php?p=background). (C) The risk score performed using multivariate Cox analysis of the three genes. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4LRPS in the TCGA model dataset. (A) Heatmap for the mRNA expression distribution in TCGA cohort by risk score, with red representing high expression and blue representing low expression. (B) The risk scores for patients with HNSCC were plotted in ascending order. (C) The survival rates of HNSCC patients between the LRPS-high group and LRPS-low group (p = 4.889 × 10−6). (D) C-index values of ROC analysis.
Figure 5Prognostic analysis of LRPS in HNSCC. (A) Univariate Cox analysis of clinicopathologic factors and the LPRS score in TCGA-HNSCC patients. (B) Multivariate Cox analysis of the significant factors according to results from the univariate Cox analysis (p < 0.05).
The differences of clinical pathological characteristics between LRPS-high and LRPS-low.
| Variables | Patients ( | LRPS-high ( | LRPS-low ( |
|
|---|---|---|---|---|
| Age at diagnosis (years) | 498 | 248 | 250 | >0.9999 |
| ≤60 | 243 | 121 | 122 | |
| >60 | 255 | 127 | 128 | |
| Gender | 498 | 248 | 250 | 0.6851 |
| Male | 366 | 180 | 186 | |
| Female | 132 | 68 | 64 | |
| Alcohol history | 487 | 241 | 246 | 0.0657 |
| Yes | 330 | 173 | 157 | |
| No | 157 | 68 | 89 | |
| Smoking history | 493 | 244 | 249 | >0.9999 |
| Yes | 488 | 242 | 246 | |
| No | 5 | 2 | 3 | |
| Clinical T stage | 483 | 243 | 240 | 0.3943 |
| T1–T2 | 175 | 93 | 82 | |
| T3–T4 | 308 | 150 | 158 | |
| Clinical stage | 484 | 243 | 241 | 0.3907 |
| I–II | 113 | 61 | 52 | |
| III–IV | 371 | 182 | 189 | |
| Histological stage | 479 | 241 | 238 | 0.9163 |
| G1–G2 | 358 | 181 | 177 | |
| G3–G4 | 121 | 60 | 61 | |
| Lymphatic metastasis | 405 | 212 | 193 | 0.6143 |
| With | 235 | 126 | 109 | |
| Without | 170 | 86 | 84 | |
| Distant metastasis | 473 | 238 | 235 | >0.9999 |
| With | 5 | 3 | 2 | |
| Without | 468 | 235 | 233 | |
| Lymphovascular invasion | 337 | 181 | 156 | 0.6492 |
| With | 119 | 66 | 53 | |
| Without | 218 | 115 | 103 | |
| Perineural invasion | 349 | 185 | 164 |
|
| With | 164 | 101 | 63 | |
| Without | 185 | 84 | 101 | |
| Recurrence | 103 | 55 | 48 |
|
| With | 40 | 29 | 11 | |
| Without | 63 | 26 | 37 |
**, level of significance, p < 0.01.
Figure 6Distribution of primary tumor sites and the HPV status in different LRPS subgroups. (A) Heatmap and table showing the distribution of HNSCC primary sites (oral cavity, pharynx, larynx, and tongue) between the LRPS subgroups. (B) Heatmap and table showing the distribution of different HPV status between the two LRPS subgroups. The distributions of the primary site subtypes and HPV status in the LRPS subgroups were compared through the Fisher test.
Figure 7Molecular characteristics of LPRS subgroups. (A) Gene sets enrichment in the LRPS-high and LRPS-low groups, respectively (p < 0.05, FDR < 0.25). (B) The proportions of immunocytes within tumor microenvironment in different LRPS subgroup (ns, no significance; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). NK cells, natural killer cells; NKT, natural killer T cells; Tgd cells, gamma delta T cells.
Figure 8Genomic mutations in the LRPS. (A) Genomic mutation signature in the patients with HNSCC from the TCGA database. (B) Significantly mutated genes in LRPS-high and LRPS-low subgroups. The top 10 mutated genes are listed; the right shows mutation percentage and the top shows the overall mutation rates of different cohorts.